Universidad Complutense De Madrid

Laboratorios Hipra, S.a.

Luis Miguel Ortega Mora

Gema Álvarez García

Aurora Fernandez Garcia

David Arranz Solís

Javier Regidor Cerrillo

Esther Collantes Fernández

David Arranz Solis

Gema Alvarez Garcia

Esther Collantes Fernandez

Silvia Rojo Montejo

The present invention relates to new protein compositions, methods for producing said protein compositions, pharmaceutical compositions comprising said protein compositions and methods for treating infections caused by. In particular, the present invention relates to a protein composition comprising the proteins specified in Table A in an amount of at least about 2 times (fold change) higher than the same protein present in the whole tachyzoite, as calculated by quantitative label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS).

vaccine composition

The invention relates to gene NcSAG4, the RNA messenger of said gene, the oligonucleotides designed based on the nucleotide sequence thereof or any of the fragments of same, and to protein NcSAG4 encoded thereby, or any of the recombinant forms of same, expression vectors, and host cells containing same, for the purpose of diagnosis and vaccination for the prevention of neosporosis. The invention also relates to the use thereof as a specific marker of thebradyzoite stage, for the analysis of the pathogenesis or the effectiveness of vaccines against the establishment of a chronic infection in the intermediate host.

Use of the gene NcSAG4 for the diagnosis and prevention of neosporosis and as a marker for analysis of the pathogenesis

Growing community of inventors

Madrid, Spain

Luis Miguel Ortega Mora